市場調査レポート

商品コード

1563381

インフルエンザワクチンの市場規模、シェア、成長分析、タイプ別、適応症別、年齢層別、流通チャネル別、地域別 - 産業予測、2024年～2031年

Influenza Vaccine Market Size, Share, Growth Analysis, By Type, By Indication, By Age Group, By Distribution Channel, By Region - Industry Forecast 2024-2031

出版日: 2024年09月25日
発行: SkyQuest
ページ情報: 英文 200 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 760,921円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 890,134円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,019,347円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.57円

全表示
概要
目次

概要

サンプル依頼リストに入れる

インフルエンザワクチンの世界市場規模は、2022年に73億9,000万米ドルと評価され、2023年の79億1,000万米ドルから2031年には135億7,000万米ドルに成長し、予測期間（2024-2031年）のCAGRは6.98％で成長する見通しです。

インフルエンザワクチン市場は、季節性インフルエンザの流行に対抗し、その健康への影響を軽減するために不可欠です。この市場には、季節性インフルエンザやパンデミックインフルエンザを含む様々なインフルエンザウイルス株から身を守るために開発された様々なワクチンが含まれています。同市場の成長を牽引しているのは、ワクチン接種の利点に関する一般市民の意識の高まりと、世界のインフルエンザ罹患率の上昇です。政府や保健機関は、公衆衛生の向上とインフルエンザ関連の合併症に関連するヘルスケアコストの削減を目的として、ワクチン接種キャンペーンを推進しています。同市場は、幅広い予防効果と有効性の向上をもたらす4価ワクチンや高用量ワクチンの登場など、ワクチン開発における絶え間ない技術革新を特徴としています。さらに、ワクチン技術や送達システムの進歩も市場の拡大に寄与しています。市場の成長にもかかわらず、市場はワクチン接種のためらいやワクチン流通における物流の問題といった課題に直面しています。

市場概要
北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域

競合情勢

上位5社の比較
主要企業の市場ポジショニング（2023年）
主な市場企業が採用した戦略
市場における最近の活動
主要企業の市場シェア（2023年）

主要企業プロファイル

GSK plc（U.K.）
Pfizer Inc.（U.S.）
Vaxess Technologies Inc.（U.S.）
Merck & Co., Inc.（U.S.）
Viatris Inc.（U.S.）
OSIVAX（France）
AstraZeneca（U.K.）
SINOVAC（China）
CSL Limited（Australia）
Emergent BioSolutions Inc.（U.S.）
Emergex Vaccines（U.K.）
Sanofi（France）
BIKEN Co., Ltd.（Japan）
Abbott（U.S.）
Altimmune Inc.（U.S.）
Baxter International Inc.（U.S.）
BioDiem Ltd（Australia）
BiondVax Pharmaceuticals Ltd.（Israel）
F. Hoffmann-La Roche Ltd.（Switzerland）
FluGen Inc.（U.S.）
Mitsubishi Chemical Group Corp.（Japan）
Novavax Inc.（U.S.）
Otsuka Holdings Co. Ltd.（Japan）
Shijiazhuang Yiling Pharmaceutical Co., Ltd.（China）
SK Chemicals Co., Ltd.（South Korea）

Product Code: SQMIG35B2144

Global Influenza Vaccine Market size was valued at USD 7.39 billion in 2022 and is poised to grow from USD 7.91 billion in 2023 to USD 13.57 billion by 2031, growing at a CAGR of 6.98% in the forecast period (2024-2031).

Influenza vaccine market is vital for combating seasonal flu outbreaks and mitigating their health impacts. This market encompasses a range of vaccines developed to protect against various strains of the influenza virus, including seasonal and pandemic flu. The market's growth is driven by increasing public awareness about the benefits of vaccination and rising incidences of influenza globally. Governments and health organizations promote vaccination campaigns to enhance public health and reduce healthcare costs associated with flu-related complications. The market is characterized by continuous innovation in vaccine development, including the advent of quadrivalent and high-dose vaccines that offer broader protection and improved efficacy. Additionally, advancements in vaccine technologies and delivery systems contribute to the market's expansion. Despite its growth, the market faces challenges such as vaccine hesitancy and logistical issues in vaccine distribution.

Top-down and bottom-up approaches were used to estimate and validate the size of the Influenza Vaccine Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Influenza Vaccine Market Segmental Analysis

Global Influenza Vaccine Market is segmented on the basis of type, indication, route of administration, age group, distribution channel, and region. By type, market is segmented into inactivated, and live attenuated. By indication, market is segmented into quadrivalent, and trivalent. By route od administration, injection, and nasal spray. By age group, market is segmented into pediatric, and adult. By distribution channel, market is segmented into hospital & pharmacies, government & institutional supply, and other. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Influenza Vaccine Market

One significant driver of the influenza vaccine market is the growing awareness and initiatives aimed at increasing vaccination rates. Public health campaigns, government policies, and educational programs have effectively raised awareness about the importance of influenza vaccination in preventing seasonal outbreaks and reducing the burden on healthcare systems. For instance, the World Health Organization (WHO) and national health agencies regularly promote vaccination to protect vulnerable populations, including the elderly, children, and individuals with chronic conditions. These initiatives not only educate the public about the benefits of vaccination but also offer subsidized or free vaccines to increase accessibility. Additionally, healthcare providers play a crucial role in recommending vaccinations and addressing concerns, which further drives vaccine uptake. This increased focus on vaccination contributes to higher immunization rates and drives market growth.

Restraints in the Influenza Vaccine Market

A significant restraint in the influenza vaccine market is vaccine hesitancy, which affects the overall vaccination rates and market growth. Vaccine hesitancy is influenced by various factors, including misinformation about vaccine safety and efficacy, personal beliefs, and concerns about potential side effects. Despite the proven effectiveness of influenza vaccines in preventing flu and reducing severe outcomes, some individuals remain reluctant to receive them due to misconceptions or lack of trust in the healthcare system. This hesitancy can lead to lower vaccination rates and contribute to outbreaks of influenza, undermining public health efforts. Addressing vaccine hesitancy requires targeted education campaigns, transparent communication from health authorities, and improved access to vaccines to build public confidence and ensure higher immunization rates.

Market Trends of the Influenza Vaccine Market

A notable trend in the influenza vaccine market is the continuous innovation in vaccine technologies. Advances in vaccine development are focused on enhancing efficacy, broadening coverage, and improving patient convenience. One such innovation is the development of quadrivalent vaccines, which protect against four different strains of the influenza virus, offering broader protection compared to traditional trivalent vaccines. Additionally, high-dose and adjuvanted vaccines are being introduced to enhance immune responses, particularly in older adults who may have weakened immune systems. The advent of new delivery systems, such as needle-free options and combination vaccines, also contributes to market growth by improving vaccine acceptance and ease of administration. These technological advancements not only aim to increase the effectiveness of influenza vaccines but also to address specific needs of various population groups, thereby driving market expansion and improving overall public health outcomes.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Pipeline Analysis
Pricing Analysis

Influenza Vaccine Market, By Type

Market Overview
Inactivated
Live Attenuated

Influenza Vaccine Market, By Indication

Market Overview
Quadrivalent
Trivalent

Influenza Vaccine Market, By Route of Administration

Market Overview
Injection
Nasal Spray

Influenza Vaccine Market, By Age Group

Market Overview
Pediatric
Adult

Influenza Vaccine Market, By Distribution Channel

Market Overview
Hospital & Pharmacies
Government & Institutional Supply
Other

Influenza Vaccine Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

GSK plc (U.K.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vaxess Technologies Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viatris Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
OSIVAX (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (U.K.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SINOVAC (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CSL Limited (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Emergent BioSolutions Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Emergex Vaccines (U.K.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BIKEN Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Altimmune Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Baxter International Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioDiem Ltd (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BiondVax Pharmaceuticals Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
FluGen Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mitsubishi Chemical Group Corp. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novavax Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Otsuka Holdings Co. Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shijiazhuang Yiling Pharmaceutical Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SK Chemicals Co., Ltd. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

インフルエンザワクチンの市場規模、シェア、成長分析、タイプ別、適応症別、年齢層別、流通チャネル別、地域別 - 産業予測、2024年～2031年

Influenza Vaccine Market Size, Share, Growth Analysis, By Type, By Indication, By Age Group, By Distribution Channel, By Region - Industry Forecast 2024-2031

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

インフルエンザワクチン市場：タイプ別

インフルエンザワクチン市場：適応症別

インフルエンザワクチン市場：投与経路別

インフルエンザワクチン市場：年齢別

インフルエンザワクチン市場：流通チャネル別

インフルエンザワクチン市場規模：地域別